{"product_id":"advances-in-metallodrugs-9781119640424","title":"Advances in Metallodrugs","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eThis book is organized into 12 important chapters that focus on the progress made by metal-based drugs as anticancer, antibacterial, antiviral, anti-inflammatory, and anti-neurodegenerative agents, as well as highlights the application areas of newly discovered metallodrugs. It can prove beneficial for researchers, investigators and scientists whose work involves inorganic and coordination chemistry, medical science, pharmacy, biotechnology and biomedical engineering.\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003ePreface xiii\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 Metallodrugs in Medicine: Present, Past, and Future Prospects 1\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eImtiyaz Yousuf and Masrat Bashir\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1.1 Introduction 2\u003c\/p\u003e \u003cp\u003e1.2 Therapeutic Metallodrugs 6\u003c\/p\u003e \u003cp\u003e1.2.1 Anticancer Metallodrugs 6\u003c\/p\u003e \u003cp\u003e1.2.1.1 Mechanism of Anticancer Action 7\u003c\/p\u003e \u003cp\u003e1.2.2 Antimicrobial and Antiviral Metallodrugs 15\u003c\/p\u003e \u003cp\u003e1.2.2.1 Antimicrobial Metallodrugs 15\u003c\/p\u003e \u003cp\u003e1.2.2.2 Antiviral Metallodrugs 16\u003c\/p\u003e \u003cp\u003e1.2.3 Radiopharmaceuticals and Radiodiagnostic Metallodrugs 17\u003c\/p\u003e \u003cp\u003e1.2.4 Anti-Diabetic Metallodrugs 19\u003c\/p\u003e \u003cp\u003e1.2.5 Catalytic Metallodrugs 22\u003c\/p\u003e \u003cp\u003e1.3 Future Prospects 23\u003c\/p\u003e \u003cp\u003e1.4 Conclusion 25\u003c\/p\u003e \u003cp\u003eReferences 26\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Chemotherapeutic Potential of Ruthenium Metal Complexes Incorporating Schiff Bases 41\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eManzoor Ahmad Malik, Parveez Gull, Ovas Ahmad Dar, Mohmmad Younus Wani, Md Ikbal Ahmed Talukdar and Athar Adil Hashmi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2.1 Introduction 42\u003c\/p\u003e \u003cp\u003e2.2 Schiff Base Complexes of Ruthenium as Anticancer Agents 43\u003c\/p\u003e \u003cp\u003e2.3 Conclusion 63\u003c\/p\u003e \u003cp\u003eReferences 64\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 Role of Metallodrugs in Medicinal Inorganic Chemistry 71\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eManish Kumar, Gyanendra Kumar, Arun Kant and Dhanraj T. Masram\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.1 Introduction 72\u003c\/p\u003e \u003cp\u003e3.2 Platinum Anticancer Drugs 74\u003c\/p\u003e \u003cp\u003e3.2.1 Nucleophilic Displacement Reactions in Complexes of Platinum 80\u003c\/p\u003e \u003cp\u003e3.2.2 Mode of the Interaction of Cisplatin Species With Nitrogen Donors of DNA Strand 80\u003c\/p\u003e \u003cp\u003e3.2.3 Systemic Toxicity of Cisplatin 82\u003c\/p\u003e \u003cp\u003e3.3 Copper-Based Anticancer Complexes 82\u003c\/p\u003e \u003cp\u003e3.3.1 Copper is Essential for Health and Nutrition 82\u003c\/p\u003e \u003cp\u003e3.3.2 Healthcare Applications of Copper 83\u003c\/p\u003e \u003cp\u003e3.3.3 Copper and Human Health Disorders 83\u003c\/p\u003e \u003cp\u003e3.3.3.1 Wilson’s Disease (WD) 84\u003c\/p\u003e \u003cp\u003e3.3.3.2 Menkes’ Disease 85\u003c\/p\u003e \u003cp\u003e3.3.4 Role of Copper Complexes as Potential Therapeutic Agents 85\u003c\/p\u003e \u003cp\u003e3.3.4.1 Thiosemicarbazones-Based Complexes 86\u003c\/p\u003e \u003cp\u003e3.3.4.2 Quinolones-Based Copper Complexes 88\u003c\/p\u003e \u003cp\u003e3.3.4.3 Naphthoquinones 88\u003c\/p\u003e \u003cp\u003e3.4 Zinc Anticancer Complexes 89\u003c\/p\u003e \u003cp\u003e3.4.1 Biologically Importance of Zinc 90\u003c\/p\u003e \u003cp\u003e3.4.2 Schiff Base Chemistry 92\u003c\/p\u003e \u003cp\u003e3.4.2.1 Schiff Base and Their Metal Complexes 92\u003c\/p\u003e \u003cp\u003e3.4.3 Zinc-Based Complexes 93\u003c\/p\u003e \u003cp\u003e3.4.4 Top Food Sources of Zinc 94\u003c\/p\u003e \u003cp\u003e3.4.5 Role of Zinc in Human Body 97\u003c\/p\u003e \u003cp\u003e3.4.6 Zinc as a Health Benefit 98\u003c\/p\u003e \u003cp\u003e3.4.7 Zinc in Alloy and Composites 100\u003c\/p\u003e \u003cp\u003e3.4.8 Zinc Supplementation as a Treatment 100\u003c\/p\u003e \u003cp\u003e3.4.8.1 Zinc Deficiency 101\u003c\/p\u003e \u003cp\u003e3.4.8.2 Zinc Toxicity 102\u003c\/p\u003e \u003cp\u003e3.4.8.3 Zinc and Viral Infections 102\u003c\/p\u003e \u003cp\u003e3.4.9 Gastrointestinal Effects 103\u003c\/p\u003e \u003cp\u003e3.5 Future Prospects of Metallodrugs 103\u003c\/p\u003e \u003cp\u003eReferences 104\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 Ferrocene-Based Metallodrugs 115\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eHamza Shoukat, Ataf Ali Altaf and Amin Badshah\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4.1 Introduction 115\u003c\/p\u003e \u003cp\u003e4.2 Ferrocene-Based Antimalarial Agents 117\u003c\/p\u003e \u003cp\u003e4.2.1 Mechanism of Action 118\u003c\/p\u003e \u003cp\u003e4.3 Ferrocene-Based Antibacterial and Antifungal Drugs 118\u003c\/p\u003e \u003cp\u003e4.3.1 Schiff Base Derived Ferrocene Conjugates as Antibacterial Agents 119\u003c\/p\u003e \u003cp\u003e4.3.2 Ferrocenyl Guanidines as Antibacterial and Antifungal Agents 121\u003c\/p\u003e \u003cp\u003e4.3.3 Sedaxicene as Antifungal Agents 122\u003c\/p\u003e \u003cp\u003e4.4 Ferrocene-Based Anti-Tumor and Anti-Cancerous Drugs 123\u003c\/p\u003e \u003cp\u003e4.4.1 Ferricenium Salts as Anti-Tumor Agents 124\u003c\/p\u003e \u003cp\u003e4.4.2 Ferrocenylalkylazoles Active Anti-Tumor Drugs 124\u003c\/p\u003e \u003cp\u003e4.4.3 Ferrocene Conjugated to Peptides for Lung Cancer 125\u003c\/p\u003e \u003cp\u003e4.4.4 Ferrocenylalkyl Nucleobases Potential Anti-Cancerous Drugs 126\u003c\/p\u003e \u003cp\u003e4.4.5 Ferrocenyl Sub-Ordinates of Illudin-M 126\u003c\/p\u003e \u003cp\u003e4.4.6 Ferrocenyl Derivatives of Retinoids Potential Anti-Tumor Drug 127\u003c\/p\u003e \u003cp\u003e4.4.7 Targeting Breast Cancer With Selective Ferrocene-Based Estrogen Receptor Modulators (SERM) 128\u003c\/p\u003e \u003cp\u003e4.5 Conclusion 131\u003c\/p\u003e \u003cp\u003e4.6 Future of Ferrocene-Based Drugs 131\u003c\/p\u003e \u003cp\u003eReferences 132\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 Recent Advances in Cobalt Derived Complexes as Potential Therapeutic Agents 137\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eManzoor Ahmad Malik, Ovas Ahmad Dar and Athar Adil Hashmi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5.1 Introduction 137\u003c\/p\u003e \u003cp\u003e5.2 Cobalt Complexes as Potential Therapeutic Agents 138\u003c\/p\u003e \u003cp\u003e5.3 Conclusion 153\u003c\/p\u003e \u003cp\u003eReferences 154\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 NO-, CO-, and H\u003csub\u003e2\u003c\/sub\u003eS-Based Metallopharmaceuticals 157\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eR. C. Maurya and J. M. Mir\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6.1 Introduction 158\u003c\/p\u003e \u003cp\u003e6.2 Signaling Molecules: Concept of “Gasotransmitter” 160\u003c\/p\u003e \u003cp\u003e6.2.1 Therapeutic Applications of NO, CO, and H\u003csub\u003e2\u003c\/sub\u003eS 162\u003c\/p\u003e \u003cp\u003e6.2.1.1 Exogenous NO Donating Molecules 163\u003c\/p\u003e \u003cp\u003e6.3 NO Donors Incorporated in Polymeric Matrices 167\u003c\/p\u003e \u003cp\u003e6.3.1 Metal Nitrosyl Complexes 168\u003c\/p\u003e \u003cp\u003e6.3.1.1 Sodium Nitroprusside (SNP) 168\u003c\/p\u003e \u003cp\u003e6.4 Dinitrosyl Iron Thiol Complexes (DNICs) 170\u003c\/p\u003e \u003cp\u003e6.5 Photoactive Transition Metal Nitrosyls as NO Donors 170\u003c\/p\u003e \u003cp\u003e6.6 Exogenous CO Donating Molecules 173\u003c\/p\u003e \u003cp\u003e6.7 H\u003csub\u003e2\u003c\/sub\u003eS Donating Compounds 176\u003c\/p\u003e \u003cp\u003e6.7.1 H\u003csub\u003e2\u003c\/sub\u003eS Gas: A Fast Delivering Compound 176\u003c\/p\u003e \u003cp\u003e6.7.2 Sulfide Salts: Fast Delivering H\u003csub\u003e2\u003c\/sub\u003eS Compounds 177\u003c\/p\u003e \u003cp\u003e6.7.3 Synthetic Moieties 178\u003c\/p\u003e \u003cp\u003e6.7.3.1 Slow-Delivering H\u003csub\u003e2\u003c\/sub\u003eS Compounds 178\u003c\/p\u003e \u003cp\u003e6.7.3.2 H\u003csub\u003e2\u003c\/sub\u003eS-Releasing Composite Compounds 179\u003c\/p\u003e \u003cp\u003e6.7.4 Naturally Occurring Plant Derived Compounds 182\u003c\/p\u003e \u003cp\u003e6.7.4.1 Garlic 182\u003c\/p\u003e \u003cp\u003e6.7.4.2 Broccoli and Other Cruciferous Vegetables 184\u003c\/p\u003e \u003cp\u003e6.8 Concluding Remarks and Future Outlook 185\u003c\/p\u003e \u003cp\u003eReferences 186\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Platinum Complexes in Medicine and in the Treatment of Cancer 203\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eRakesh Kumar Ameta and Parth Malik\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7.1 What is Cancer? 203\u003c\/p\u003e \u003cp\u003e7.1.1 Characteristic Features of Cancer Cells 205\u003c\/p\u003e \u003cp\u003e7.1.2 Definition of Anticancer Compound 206\u003c\/p\u003e \u003cp\u003e7.1.3 Anticancer Attributes of Pt Complexes 207\u003c\/p\u003e \u003cp\u003e7.1.4 Native State Behavior of Pt Complexes 208\u003c\/p\u003e \u003cp\u003e7.2 Compatibility of Pt Compounds in Cancer Treatment 209\u003c\/p\u003e \u003cp\u003e7.2.1 Significance of DNA as Primary Target 209\u003c\/p\u003e \u003cp\u003e7.2.2 Kinetics of DNA Binding Activities 210\u003c\/p\u003e \u003cp\u003e7.2.3 Structural and Regioselectivity of DNA Adducts 210\u003c\/p\u003e \u003cp\u003e7.2.4 Studies on Action Mechanism 211\u003c\/p\u003e \u003cp\u003e7.3 Pt Complexes as Anticancer Drugs 214\u003c\/p\u003e \u003cp\u003e7.3.1 DNA-Coordinating Pt(II) Complexes 214\u003c\/p\u003e \u003cp\u003e7.3.2 DNA-Covalently Binding Pt(II) Complexes 219\u003c\/p\u003e \u003cp\u003e7.3.3 Targeted Pt(II) Complexes 222\u003c\/p\u003e \u003cp\u003e7.3.4 Pt(IV) Prodrugs 224\u003c\/p\u003e \u003cp\u003e7.3.5 Multiple Action of Pt(IV) Prodrugs 225\u003c\/p\u003e \u003cp\u003e7.3.6 Targeted Pt(IV) Prodrugs 228\u003c\/p\u003e \u003cp\u003e7.3.7 Photodynamic Killing of Cancer Cell by Pt Complexes 231\u003c\/p\u003e \u003cp\u003e7.4 Conclusion 231\u003c\/p\u003e \u003cp\u003eAcknowledgments 232\u003c\/p\u003e \u003cp\u003eReferences 232\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 Recent Advances in Gold Complexes as Anticancer Agents 247\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eMohammad Nadeem Lone, Zubaid-ul-khazir, Ghulam Nabi Yatoo, Javid A. Banday and Irshad A. Wani\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8.1 Introduction 248\u003c\/p\u003e \u003cp\u003e8.2 Evolution of Metal Complexes as Anticancer Agents 250\u003c\/p\u003e \u003cp\u003e8.3 Gold Complexes 251\u003c\/p\u003e \u003cp\u003e8.3.1 Complexes with Nitrogen Donar Ligands 252\u003c\/p\u003e \u003cp\u003e8.3.2 Complexes with Sulphur Donar Ligands 254\u003c\/p\u003e \u003cp\u003e8.3.3 Complexes with Phosphorus Donar Ligands 255\u003c\/p\u003e \u003cp\u003e8.3.4 Complexes with Sulphur-Phosphorus Donar Ligands 256\u003c\/p\u003e \u003cp\u003e8.3.5 Organometallic Gold Complexes 259\u003c\/p\u003e \u003cp\u003e8.3.6 Miscellaneous 260\u003c\/p\u003e \u003cp\u003e8.4 Nano-Formulations of Gold Complexes 262\u003c\/p\u003e \u003cp\u003e8.5 Future Challenges and Perspectives 263\u003c\/p\u003e \u003cp\u003e8.6 Conclusion 265\u003c\/p\u003e \u003cp\u003eAcknowledgements 266\u003c\/p\u003e \u003cp\u003eReferences 266\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 Recent Developments in Small Molecular HIV-1 and Hepatitis B Virus RNase H Inhibitors 273\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eFenju Wei, Dongwei Kang, Luis Menéndez-Arias, Xinyong Liu and Peng Zhan\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9.1 Introduction 273\u003c\/p\u003e \u003cp\u003e9.1.1 Activity and Function of HIV and HBV RNases H 274\u003c\/p\u003e \u003cp\u003e9.1.2 The Metal-Chelating RNase H Active Site 274\u003c\/p\u003e \u003cp\u003e9.2 RNase H Inhibitors and Strategies in the Discovery of Active Compounds 276\u003c\/p\u003e \u003cp\u003e9.2.1 High-Throughput Screening 276\u003c\/p\u003e \u003cp\u003e9.2.2 Design Based on Pharmacophore Models 278\u003c\/p\u003e \u003cp\u003e9.2.3 Novel Inhibitors Obtained by Using “Click Chemistry” 279\u003c\/p\u003e \u003cp\u003e9.2.4 Dual-Target Inhibitors Against HIV-1 Integrase (IN) and RNase H 280\u003c\/p\u003e \u003cp\u003e9.2.5 Inhibitors Obtained by Using Privileged Fragment-Based Libraries 282\u003c\/p\u003e \u003cp\u003e9.2.6 RNase H Inhibitors in Natural Products 283\u003c\/p\u003e \u003cp\u003e9.2.7 Drug Repurposing Based on Privileged Structures 284\u003c\/p\u003e \u003cp\u003e9.3 Conclusion 286\u003c\/p\u003e \u003cp\u003eReferences 287\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10 The Role of Metals and Metallodrugs in the Modulation of Angiogenesis 293\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eMehmet Varol and Tuğba Ören Varol\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10.1 Introduction 294\u003c\/p\u003e \u003cp\u003e10.2 Metallodrugs in Anticancer Therapy 297\u003c\/p\u003e \u003cp\u003e10.3 Angiogenesis as a Substantial Target of Tumorigenesis 300\u003c\/p\u003e \u003cp\u003e10.4 Metals and Metallodrugs in Angiogenesis 302\u003c\/p\u003e \u003cp\u003e10.5 Concluding Remarks and Future Prospects 306\u003c\/p\u003e \u003cp\u003eReferences 306\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11 Metal-Based Cellulose: An Attractive Approach Towards Biomedicine Applications 319\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eKulsoom Koser and Athar Adil Hashmi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11.1 Introduction 320\u003c\/p\u003e \u003cp\u003e11.2 History of Cellulose 320\u003c\/p\u003e \u003cp\u003e11.3 The Properties and Structure of Cellulose 321\u003c\/p\u003e \u003cp\u003e11.4 Modification of Cellulose 322\u003c\/p\u003e \u003cp\u003e11.4.1 Acid Hydrolysis 322\u003c\/p\u003e \u003cp\u003e11.4.2 Oxidation 324\u003c\/p\u003e \u003cp\u003e11.4.3 Esterification 326\u003c\/p\u003e \u003cp\u003e11.4.4 Amidation 331\u003c\/p\u003e \u003cp\u003e11.4.5 Carbamiation 333\u003c\/p\u003e \u003cp\u003e11.4.6 Etherification 336\u003c\/p\u003e \u003cp\u003e11.4.7 Nucleophilic Substitution 339\u003c\/p\u003e \u003cp\u003e11.4.8 Further Modification 341\u003c\/p\u003e \u003cp\u003e11.5 Present and Future Medical Applications of Cellulose as Well as Its Components 344\u003c\/p\u003e \u003cp\u003e11.5.1 Cellulose Used as Wound Dressing 344\u003c\/p\u003e \u003cp\u003e11.5.2 Dental Applications 345\u003c\/p\u003e \u003cp\u003e11.5.3 Engineering 346\u003c\/p\u003e \u003cp\u003e11.5.4 Controllable Drug Delivery System 348\u003c\/p\u003e \u003cp\u003e11.5.5 Blood Purification 348\u003c\/p\u003e \u003cp\u003e11.5.6 Wrapping Purpose 350\u003c\/p\u003e \u003cp\u003e11.5.7 Renal Failure 351\u003c\/p\u003e \u003cp\u003e11.6 Conclusion 351\u003c\/p\u003e \u003cp\u003eReferences 352\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12 Multifunctional Nanomedicine 363\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eNobel Tomar, Maroof A. Hashmi and Athar Adil Hashmi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12.1 Introduction 364\u003c\/p\u003e \u003cp\u003e12.2 Diagnostics and Imaging 366\u003c\/p\u003e \u003cp\u003e12.3 Drug Delivery and Therapy 369\u003c\/p\u003e \u003cp\u003e12.3.1 Drug Delivery by Organic Nanomaterials 369\u003c\/p\u003e \u003cp\u003e12.3.1.1 Liposomal Drug Delivery 369\u003c\/p\u003e \u003cp\u003e12.3.1.2 Polymeric Drug Delivery 371\u003c\/p\u003e \u003cp\u003e12.3.1.3 Proteins and Peptides for Drug Delivery 373\u003c\/p\u003e \u003cp\u003e2.3.2 Drug Delivery by Inorganic Nanomaterials 374\u003c\/p\u003e \u003cp\u003e12.3.2.1 Metal and Metal Oxides 374\u003c\/p\u003e \u003cp\u003e12.3.2.2 Au NPs 375\u003c\/p\u003e \u003cp\u003e12.3.2.3 Carbon-Based NPs 375\u003c\/p\u003e \u003cp\u003e12.3.2.4 Silicon-Based Nanostructures for Drug Delivery 378\u003c\/p\u003e \u003cp\u003e12.3.3 Photo Therapy 379\u003c\/p\u003e \u003cp\u003e12.3.3.1 Photodynamic Therapy 380\u003c\/p\u003e \u003cp\u003e12.3.3.2 Photothermal Therapy 381\u003c\/p\u003e \u003cp\u003e12.3.4 Radiation Therapy 383\u003c\/p\u003e \u003cp\u003e12.3.5 Neutron Capture Therapy 384\u003c\/p\u003e \u003cp\u003e12.4 Regenerative Medicine 385\u003c\/p\u003e \u003cp\u003e12.5 Future Prospects and Conclusion 386\u003c\/p\u003e \u003cp\u003eReferences 387\u003c\/p\u003e \u003cp\u003eIndex 403\u003c\/p\u003e","brand":"John Wiley \u0026 Sons Inc","offers":[{"title":"Default Title","offer_id":49407106482519,"sku":"9781119640424","price":169.16,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781119640424.jpg?v=1730498198","url":"https:\/\/bookcurl.com\/products\/advances-in-metallodrugs-9781119640424","provider":"Book Curl","version":"1.0","type":"link"}